These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 34769197)
1. Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. Fondevila F; Méndez-Blanco C; Fernández-Palanca P; Payo-Serafín T; van Pelt J; Verslype C; González-Gallego J; Mauriz JL Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769197 [TBL] [Abstract][Full Text] [Related]
2. RNA m Lin Z; Niu Y; Wan A; Chen D; Liang H; Chen X; Sun L; Zhan S; Chen L; Cheng C; Zhang X; Bu X; He W; Wan G EMBO J; 2020 Jun; 39(12):e103181. PubMed ID: 32368828 [TBL] [Abstract][Full Text] [Related]
3. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413 [TBL] [Abstract][Full Text] [Related]
5. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma. Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812 [TBL] [Abstract][Full Text] [Related]
9. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380 [TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma. De Mattia E; Cecchin E; Guardascione M; Foltran L; Di Raimo T; Angelini F; D'Andrea M; Toffoli G World J Gastroenterol; 2019 Aug; 25(29):3870-3896. PubMed ID: 31413525 [TBL] [Abstract][Full Text] [Related]
11. Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. Chen W; Yang J; Zhang Y; Cai H; Chen X; Sun D FEBS Open Bio; 2019 Feb; 9(2):335-347. PubMed ID: 30761258 [TBL] [Abstract][Full Text] [Related]
12. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Yang PM; Lin LS; Liu TP Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661 [TBL] [Abstract][Full Text] [Related]
13. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma. Li D; Yao Y; Rao Y; Huang X; Wei L; You Z; Zheng G; Hou X; Su Y; Varghese Z; Moorhead JF; Chen Y; Ruan XZ J Exp Clin Cancer Res; 2022 Mar; 41(1):116. PubMed ID: 35354475 [TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells. Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434 [TBL] [Abstract][Full Text] [Related]
15. Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression. Kim HY; Jung HU; Yoo SH; Yoo KS; Cheong J; Park BS; Yun I; Yoo YH Cancer Lett; 2014 Dec; 355(1):61-9. PubMed ID: 25218348 [TBL] [Abstract][Full Text] [Related]
17. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890 [TBL] [Abstract][Full Text] [Related]
18. Silencing Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790 [TBL] [Abstract][Full Text] [Related]
19. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma. Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma. Liu D; Fan Y; Li J; Cheng B; Lin W; Li X; Du J; Ling C Oncol Rep; 2018 Oct; 40(4):2206-2214. PubMed ID: 30066934 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]